According to the latest report, a new stake in the BioMarin Pharmaceuticals has been acquired by the Mercer Global Advisors Inc. in the first quarter. The fund got the acquisition of 2641 shares of the stock of the biotech company which were valued at an estimate of $235K
Various other investors also either reduced or added to their stakes in the business
Recently. Commonwealth Bank of Australia got the acquisition of 350 shares of the stock of the biotech company which worth the value of $29K after getting the acquisition of extra 116 shares in the 4th quarter. This rose the share’ stake by 49.6 percent. A new stake which was of worth $26K was bought by the Doyle Wealth Management in the shares of the BioMarin Pharmaceuticals Inc. which led to the rise in stake.
Furthermore, Lindbrook Capital LLC purchased a new stake in the shares of the BioMarin Pharmaceutical Inc. during the last quarter which of around the worth of $30K. PRW Wealth Management also purchased a new stake which was also of worth 30,000. Lastly, Lake Point Wealth Management purchased a new stake in the shares of the BioMarin Pharmaceutical Inc. during the last quarter which was of the approximate worth of $34K. around 98% of the stock of the company is owned by the institutional investors.
The quarterly earnings data of the BioMarin Pharmaceutical Inc. was released on the 25th of April i.e. on Thursday. The biotech company has reported the earnings per shares for the quarter. Also, the net margin of the company was of 5.90% and there was a negative return on the capital equity of 2.97 percent. In the last quarter, the total revenue earned by the company was $400.70 million comparative to the expectations of the $389.95 Million.